Pathophysiology and treatment of lipid perturbation after cardiac transplantation

Christie M. Ballantyne, Bassem El Masri, Joel D. Morrisett, Guillermo Torre

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


In this review we examine the complex interactions between lipoprotein metabolism, immunosuppressive drug therapy, and inflammation and the potential benefits of lipid-lowering drug therapy after heart transplantation. The newer formulations of cyclosporine, Neoral (Novartis Pharmaceuticals; Basle, Switzerland), and other newer agents such as tacrolimus may have advantages in regard to lipid metabolism as compared with traditional triple-drug immunosuppression. Lipoprotein levels may influence both the toxicity and efficacy of cyclosporine. Dyslipidemia may adversely influence inflammation and rejection in the allograft. Two recent clinical trials have shown that lipid-lowering therapy with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor alone or in combination with low-density lipoprotein apheresis may confer significant benefits toward preventing transplant coronary artery disease.

Original languageEnglish (US)
Pages (from-to)153-160
Number of pages8
JournalCurrent Opinion in Cardiology
Issue number2
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pathophysiology and treatment of lipid perturbation after cardiac transplantation'. Together they form a unique fingerprint.

Cite this